Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Novartis: Clinical Trials & FDA Approval Profile

Novartis (Basel, CH / East Hanover, NJ) sponsors 492 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 179 active protocols (80 recruiting now), 194 completed protocols, and 224 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)24.2%
Median Closed Enrollment vs National (145 pts)119 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Novartis
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)492
Active Pipeline (Recruiting Now)179 (80)
Completed vs Stopped Early194 / 119 (24.2%)
Median Closed Actual Enrollment119 participants
Physical Hospital Site Disclosure22.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals224 (29 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Novartis
Hospital Research SiteLocationShared Protocols
Massachusetts General HospitalBoston, MA34
Stanford Health Care and Stanford Cancer InstituteStanford, CA30
Emory Winship Cancer InstituteAtlanta, GA27

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Novartis
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07768371A 52-week Study of Remibrutinib in IgE-mediated Food AllergyPhase IIIRECRUITING
NCT06997588EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult PatienPhase IIRECRUITING
NCT05939414An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.Phase IIIRECRUITING
NCT05646381A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StePhase IIRECRUITING
NCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Novartis Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI